Comparing the current results to its competitors, Northwest Biotherapeutics Inc reported Revenue increase in the 2 quarter 2026 by 516.03 % year on year. The sales growth was above Northwest Biotherapeutics Inc's competitors' average revenue growth of 33.42 %, achieved in the same quarter.
Northwest Biotherapeutics Inc's Comment on Competition and Industry Peers
The company operates in a competitive environment for developing brain cancer treatments, facing competition from biopharmaceutical, biotechnology, and pharmaceutical companies, as well as academic institutions, research organizations, and some medical device companies. Key competing products include Avastin (Roche Holding AG), Gliadel (Eisai Co. Ltd.), Temodar (Merck & Co., Inc.), the Optune electro-therapy device (Novocure), and oncolytic viruses. Additionally, checkpoint inhibitor drugs and T cell-based therapies are undergoing clinical trials for solid tumors, including brain cancer. Competitors often possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, marketing, and sales. Smaller or early-stage companies may also present competition, particularly when collaborating with larger established firms. Competition extends to recruiting qualified personnel, acquiring complementary technologies, and securing clinical trial sites.
Due to outstanding performance in Overall company, revenue grew by 516.03 % Northwest Biotherapeutics Inc improved its market share, to approximately 0.38 %.
Xencor Inc is a biotechnology company that primarily focuses on the development of therapeutic antibodies. Their business model revolves around utilizing their proprietary XmAb® technology to engineer antibodies with enhanced properties for the treatment of various diseases. They collaborate with pharmaceutical companies to develop and commercialize these antibody therapeutics, generating revenue through upfront payments, milestone payments, and royalties.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing and commercializing innovative therapies for psychiatric and neurological conditions. Their business model revolves around identifying potential drug candidates, conducting preclinical and clinical trials to evaluate their efficacy and safety, and ultimately obtaining regulatory approval for their products to bring them to market. Through strategic partnerships and collaborations, they aim to commercialize and distribute their therapies to provide much-needed treatment options for patients.
TG Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative treatments for patients with hematological malignancies and autoimmune diseases.
Sources:
Northwest Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Northwest Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
